EuMederis Pharmaceuticals carries out design and development of Best in Class peptide pharmaceuticals with improved bioavailability and prolonged duration of action. Our proprietary, non-peptide modification (EuPort) allows rapid identification of best in class clinical candidates. The EuPort platform modification was designed specifically to improve the bioavailability and duration of action of peptide pharmaceuticals. EuPort-modified peptides thus are proprietary new chemical entities with improved and marketable pharmaceutical properties. Proof of concept was carried out in osteoporosis, where a fragment of the native parathyroid hormone (PTH1-34; Forteo, Lilly) was further truncated and coupled to the EuPort modification. The resulting molecules have low nanomolar potency and super-agonistic efficacy (cAMP) in human cellular assays, Very prolonged efficacy with no hypercalcemia was demonstrated in vivo. Eu-232 was selected as a clinical candidate. Modification of an endogenous opioid peptide with the EuPort technology yielded Eu-178, with low nM potency on the mu opioid (morphine-like) receptor and sub-nM antagonistic potency on the delta opioid receptor, a profile for peripheral analgesia with no central side effects (no respiratory depression, euphoria, or addiction). EuMederis is seeking investors and commercialization partners to bring our preclinical candidates in osteoporosis, pain and asthma into clinical trials. See the website.